Recently, a combination therapy regimen with an anti-programmed cell death 1-ligand 1 (PD-L1) antibody (atezolizumab), and an anti-vascular endothelial growth factor (VEGF) antibody (bevacizumab) was recommended as the first-line systemic therapy for advanced-stage HCC, as defined by the modified Barcelona Clinic Liver Cancer staging system, at the American Association for the Study of Liver Diseases (AASLD) consensus conference [2,3]. Here, VEGFA is linked to hepatocellular carcinoma.